Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

108 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Highlights in Head and Neck Cancer.
Chau NG, Tishler RB, Haddad RI. Chau NG, et al. JAMA Oncol. 2017 Apr 1;3(4):441-442. doi: 10.1001/jamaoncol.2016.3648. JAMA Oncol. 2017. PMID: 27893016 No abstract available.
Frameshift events predict anti-PD-1/L1 response in head and neck cancer.
Hanna GJ, Lizotte P, Cavanaugh M, Kuo FC, Shivdasani P, Frieden A, Chau NG, Schoenfeld JD, Lorch JH, Uppaluri R, MacConaill LE, Haddad RI. Hanna GJ, et al. Among authors: chau ng. JCI Insight. 2018 Feb 22;3(4):e98811. doi: 10.1172/jci.insight.98811. eCollection 2018 Feb 22. JCI Insight. 2018. PMID: 29467336 Free PMC article.
A Phase 1 Study of Afatinib in Combination with Postoperative Radiation Therapy with and Without Weekly Docetaxel in Intermediate- and High-Risk Patients with Resected Squamous Cell Carcinoma of the Head and Neck.
Margalit DN, Haddad RI, Tishler RB, Chau NG, Schoenfeld JD, Bakst RL, Misiukiewicz KJ, Gupta V, Posner M, Hanna GJ, Mahmood U, Rawal B, Catalano PJ, Rath L, Bacay A, McHugh P, Rabinowits G. Margalit DN, et al. Among authors: chau ng. Int J Radiat Oncol Biol Phys. 2019 Sep 1;105(1):132-139. doi: 10.1016/j.ijrobp.2019.04.034. Epub 2019 May 11. Int J Radiat Oncol Biol Phys. 2019. PMID: 31082494 Clinical Trial.
Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open-Label Randomized Clinical Trial.
Schoenfeld JD, Hanna GJ, Jo VY, Rawal B, Chen YH, Catalano PS, Lako A, Ciantra Z, Weirather JL, Criscitiello S, Luoma A, Chau N, Lorch J, Kass JI, Annino D, Goguen L, Desai A, Ross B, Shah HJ, Jacene HA, Margalit DN, Tishler RB, Wucherpfennig KW, Rodig SJ, Uppaluri R, Haddad RI. Schoenfeld JD, et al. JAMA Oncol. 2020 Oct 1;6(10):1563-1570. doi: 10.1001/jamaoncol.2020.2955. JAMA Oncol. 2020. PMID: 32852531 Free PMC article. Clinical Trial.
108 results